Paris
The results confirm observations from the US, the UK and Israel, but researchers say it is the largest study of its kind so far.
Looking at data collected starting in December 2020, when France launched its jab campaign, the researchers compared the outcomes of 11 million vaccinated people with 11 million unvaccinated subjects.
They formed pairs matching an unvaccinated individual with a vaccinated counterpart from the same region and of the same age and sex, tracking them from the date of the vaccinated person's second jab to July 20.
Starting 14 days after a second dose, a vaccinated subjects' risk of severe Covid was reduced by 90 percent, according to the research conducted by Epi-Phare, an independent medicines safety research group that works closes with the French government.
Vaccination appears to be nearly as effective against for the Delta variant, with 84 percent protection for people 75 and older and 92 percent for people 50-75.
That estimate, however, is only based on a month of data, since the variant became dominant in France only in June.
"The study should be followed up to include results from August and September," epidemiologist Mahmoud Zureik, the head of Epi-Phare, told AFP.
The study covers vaccination with the Pfizer/BioNtech, Moderna and AstraZeneca jabs, but not Jannsen which was authorised much later and is far less widely used in France
Visit news.dtnext.in to explore our interactive epaper!
Download the DT Next app for more exciting features!
Click here for iOS
Click here for Android